An official website of the United States government
Home
| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J9329 | Tislelizumab-jsgr | Tevimbra | 1mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2024 | Sep 11, 2024 | In Use | ||
| C9169 | Nogapendekin alfa inbakicept-pmln | Anktiva | 1 microgram | Immunotherapy | Cytokine | IL-15 (⍺,β,ɣ) | No | 2024 | Sep 11, 2024 | Mar 26, 2025 | No Longer Used | |
| Lazertinib | Lazcluze | 80mg, 240mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2024 | In Use | ||||
| J9382 | Zenocutuzumab-zbco | Bizengri | 1mg | Immunotherapy | Bispecific Antibody | HER2, HER3 | No | 2024 | Jul 9, 2025 | In Use | ||
| C9303 | Zolbetuximab-clzb | Vyloy | 1mg | Immunotherapy | Monoclonal Antibody | CLDN18.2 | No | 2024 | Mar 26, 2025 | Jul 9, 2025 | No Longer Used | |
| J9054 | Bortezomib (boruzu) | Boruzu | 0.1mg | Chemotherapy | Proteasome Inhibitor | 26S | No | 2024 | Mar 26, 2025 | In Use | ||
| J9076 | Cyclophosphamide (Baxter) | Cyclophosphamide (Baxter) | 5mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2024 | Dec 17, 2024 | In Use | ||
| C9170 | Tarlatamab-dlle, 1 mg | IMDELLTRA | 1mg | Immunotherapy | T Cell Receptor (TCR) | DLL3, CD3 | No | 2024 | Sep 11, 2024 | Dec 17, 2024 | No Longer Used | |
| Q5148 | Filgrastim-txid (nypozi) | Nypozi | 1 microgram | Ancillary Therapy | Immunostimulant | Colony-Stimulating Factor | No | 2024 | Mar 26, 2025 | In Use | ||
| C9173 | Filgrastim-txid (nypozi) | Nypozi | 1 mcg | Ancillary Therapy | Immunostimulant | Colony-Stimulating Factor | No | 2024 | Dec 17, 2024 | Jul 9, 2025 | In Use | |
| J9174 | Docetaxel (beizray) | Beizray | 1mg | Chemotherapy | Antimitotic Agent | Taxane | No | 2024 | Jul 9, 2025 | In Use | ||
| Tovorafenib | Ojemda | 25mg, 100mg | Chemotherapy | Enzyme Inhibitor | BRAF, CRAF | Yes | 2024 | In Use | ||||
| J9024 | Atezolizumab, hyaluronidase-tqjs | Tecentriq Hybreza | 5mg | Immunotherapy | Checkpoint Inhibitor | PD-L1 | No | 2024 | Mar 26, 2025 | In Use | ||
| C9301 | Obecabtagene car pos t (Obecabtagene autoleucel) | AUCATZYL | up to 400 million | Immunotherapy | CAR-T | CD-19 | No | 2024 | Mar 26, 2025 | Jul 9, 2025 | No Longer Used | |
| Vorasidenib | Voranigo | 10mg,40mg | Chemotherapy | IDH Inhibitor | IDH1, IDH2 | Yes | 2024 | In Use | ||||
| Q2058 | Obecabtagene autoleucel | AUCATZYL | up to 400 million | Immunotherapy | CAR-T | CD-19 | No | 2024 | Jul 9, 2025 | In Use | ||
| Revumenib | Revuforj | 25mg, 110mg, 160mg | Chemotherapy | Enzyme Inhibitor | KMT2A | Yes | 2024 | In Use | ||||
| Q2057 | Afamitresgene autoleucel | Tecelra | per therapeutic dose | Immunotherapy | T Cell Receptor (TCR) | MAGE-A4 | No | 2024 | Mar 26, 2025 | In Use | ||
| J9276 | Zanidatamab-hrii | ZIIHERA | 2mg | Immunotherapy | Bispecific Antibody | HER2 | No | 2024 | Jul 9, 2025 | In Use | ||
| J0870 | Imetelstat | Rytelo | 1mg | Chemotherapy | Enzyme Inhibitor | Telomerase | No | 2024 | Dec 17, 2024 | In Use | ||
| Inavolisib | Itovebi | 3mg, 9mg | Chemotherapy | Enzyme Inhibitor | PI3K⍺ | Yes | 2024 | In Use | ||||
| Inovolisib | Itovebi | 3mg, 9mg | Chemotherapy | Enzyme Inhibitor | PI3K⍺ | Yes | 2024 | In Use | ||||
| C9302 | Zanidatamab-hrii | ZIIHERA | 2mg | Immunotherapy | Bispecific Antibody | HER2 | No | 2024 | Mar 26, 2025 | Jul 9, 2025 | No Longer Used | |
| J9026 | Tarlatamab-dlle | IMDELLTRA | 1mg | Immunotherapy | T Cell Receptor (TCR) | DLL3, CD3 | No | 2024 | Dec 17, 2024 | In Use | ||
| Q5160 | Bevacizumab-nwgd (Jobevne) | Jobevne | 10mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2025 | Jan 1, 2026 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
